APG-2449 in Patients With Advanced Solid Tumors

NCT03917043 · readout ≤ 499 d

Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With Suzhou Yasheng Pharmaceutical Co., Ltd..

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

165estimated

Sites

Country

China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2019-05-27

actual

When the study began enrolling

Primary completion

Dec 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2028

estimated

The whole study's end, after follow-up

First posted

2019-04-16

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Advanced Solid Cancer
Non Small Cell Lung Cancer
Esophageal Cancer
Ovarian Cancer
Malignant Pleural Mesothelioma

Intervention

Drug: APG-2449 — also filed as APG-2449 Capsule

Primary outcomes

what the primary-completion date above is the date OF

Maximum Tolerated Dose (MTD)

measured 28 days

Recommended Phase 2 dose (RP2D)

measured 28 days

Publications

PMID 41146927 — linked by the registry
PMID 35820889 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed